BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 33293694)

  • 1. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
    Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
    Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
    Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
    Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET inhibition induces synthetic lethality in PTEN deficient colorectal cancers via dual action on p21
    Ren G; Chen J; Pu Y; Yang EJ; Tao S; Mou PK; Chen LJ; Zhu W; Chan KL; Luo G; Deng C; Shim JS
    Int J Biol Sci; 2024; 20(6):1978-1991. PubMed ID: 38617536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade.
    Zhang B; Leng C; Wu C; Zhang Z; Dou L; Luo X; Zhang B; Chen X
    Oncol Rep; 2016 Mar; 35(3):1807-15. PubMed ID: 26647806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
    Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
    Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
    Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
    Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
    Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
    Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
    Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation.
    Shi C; Tao S; Ren G; Yang EJ; Shu X; Mou PK; Liu Y; Dang Y; Xu X; Shim JS
    Oncogene; 2022 May; 41(19):2734-2748. PubMed ID: 35393542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
    Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
    Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
    Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pien Tze Huang Inhibits Proliferation of Colorectal Cancer Cells through Suppressing PNO1 Expression and Activating p53/p21 Signaling Pathway.
    Cao LJ; Liu LY; Chen YQ; Han YY; Wei LH; Yao MY; Fang Y; Wu MZ; Cheng Y; Sferra TJ; Liu HX; Li L; Peng J; Shen AL
    Chin J Integr Med; 2024 Jun; 30(6):515-524. PubMed ID: 38216838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
    Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
    Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
    [No Abstract]   [Full Text] [Related]  

  • 18. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
    Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
    Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of c-Myc enhances p21
    Jeong YJ; Hoe HS; Cho HJ; Park KK; Kim DD; Kim CH; Magae J; Kang DW; Lee SR; Chang YC
    J Cell Biochem; 2018 Feb; 119(2):2036-2047. PubMed ID: 28833404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.